Treatments using venlafaxine

Details Treatments using venlafaxine Treatments using venlafaxine

2001-06-27

2002-10-15

Travers, Russell (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S653000, C514S654000

Reexamination Certificate

active

06465524

ABSTRACT:

BACKGROUND OF THE INVENTION
The active ingredients of this invention include (1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol), or therapeutically acceptable salts thereof, which are known generally as venlafaxine and its analogues. Venlafaxine is disclosed in U.S. Pat. No. 4,535,186 (Husbands et al.) and has been previously reported to be useful as an antidepressant. U.S. Pat. No. 4,535,186 teaches the production of venlafaxine and its analogues and is incorporated herein as reference. For the purposes of this disclosure, and the claims that follow, the use of venlafaxine is understood to include the free base and pharmaceutically acceptable salt forms of venlafaxine, the racemate and its individual enantiomers, and venlafaxine analogs, both as racemates and as their individual enantiomers.
Venlafaxine has been shown to be a potent inhibitor of monoamine neurotransmitter uptake, a mechanism associated with clinical antidepressant activity. Due to its novel structure, venlafaxine has a mechanism of action unrelated to other available antidepressants, such as the tricyclic antidepressants desipramine, nostriptyline, protriptyline, imipramine, amitryptyline, trimipramine and doxepin.
It is believed that venlafaxine's mechanism of action is related to potent inhibition of the uptake of the monoamine neurotransmitters serotonin and norepinephrine. To a lesser degree, venlafaxine also inhibits dopamine reuptake, but it has no inhibitory activity on monoamine oxidase. O-desmethylvenlafaxine, venlafaxine's major metabolite in humans, exhibits a similar pharmacologic profile. Venlafaxine's ability to inhibit norepinephrine and serotonin (5-HT) uptake has been predicted to have an efficacy which rivals or surpases that of tricyclic antidepressants (Stuart A. Montgomery, M.D., J. Clin. Psychiatry, 54:3, March 1993).
In contrast to classical tricyclic antidepressant drugs, venlafaxine has virtually no affinity for muscarinic, histaminergic or adrenergic receptors in vitro. Pharmacologic activity at these receptors is associated with the various anticholinergic, sedative and cardiovascular effects seen with the tricyclic antidepressant drugs.


REFERENCES:
patent: 4535186 (1985-08-01), Husbands et al.
patent: 4609758 (1986-09-01), Husbands
patent: 4611078 (1986-09-01), Husbands et al.
patent: 4761501 (1988-08-01), Husbands et al.
patent: 4824868 (1989-04-01), Watthey
patent: 4956388 (1990-09-01), Robertson et al.
patent: 4996235 (1991-02-01), Robertson et al.
patent: 5006525 (1991-04-01), Schaus
patent: 5013761 (1991-05-01), Beedle et al.
patent: 5023269 (1991-06-01), Robertson et al.
patent: 5057515 (1991-10-01), Schaus
patent: 5135947 (1992-08-01), Robertson et al.
patent: 0449562 (1991-03-01), None
Fluoxetine—A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Depressive Illness. Drugs 32: 481-508 (1986).
Serotonergic Mechanisms in the Behavioral Effects of Buspirone and Gepirone. Eison et al., Pharm. Bioch. and Behavior, vol. 24, pp. 701-707, 1986.
Dexfenfluramine—Its Place in Weight Control. Turner, Drugs 39 (Suppl. 3): 53-62, 1990.
Dosing Strategies for Antidepressant Agents. Schatzburg, J. Clin. Psychiatry 52:5 (suppl.), May 1991.
Fluoxetine: A Serotonergic Appetite Suppressant Drug. Fuller and Wong, Drug Development Research 17: 1-15 (1989).
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity. Yardley et al., J. Med. Chem., 1990, 33.
Venlafaxine: A New Dimension in Antidepressant Pharmacology, Montgomery, J. Clin. Psychiatry 54:3, Mar. 1993.
Dexfenfluramine—A Review of Its Pharmacological Properties and Therapeutic Potential in Obesity, McTavish et al., Drigs 43(5): 713-733, 1992.
Appetite Suppressants—A Review, Silverstone, Drugs 43(6): 820-836, 1992.
Fontana et al., Psychopharmacology, 95:147-150 (1988).
Bodnoff et al., Psychopharmacology, 97:277-279 (1989).
Bodnoff et al., Psychopharmacology, 95:298-302 (1988).
Lydiard, J. Clin. Psychiatry, 52:6(suppl), Jun. 1991.
Rickels, et al., Arch. Gen. Psychiatry, vol. 50, Nov. 1993.
Kahn, et al., Arch. Gen Psychiatry, vol. 43, Jan. 1986.
Fonzo, et al., Acta Psychiatr Scand, 95:444-450, 1997.
Davies et al., The Journal of Nervous and Mental Disease, vol. 183, No. 1, 1995.
Rickels, et al., J. Clin. Psychiatry, 54:1 (suppl), Jan. 1993.
Anderson, et al., Am. J. Psychiatry 141:4, Apr. 1984.
Barlow, et al., Am. J. Psychiatry, 143:1, Jan. 1986.
Kahn, et al., Journal of Affective Disorders, 13, 145-151 (1987).
Brown, et al., Am. J. Psychiatry, 151:9, Sep. 1994.
Sanderson et al., The Journal of Nervous and Mental Disease, vol. 178, No. 9, 1990.
Wingerson et al., J. Clin. Psychopharmacology, vol. 12, No. 3, Jun. 1992.
Wilcox et al., Prog. Neuro-Psychopharmacol. & Biol. Psychiat. vol. 18, 979-993, 1994.
Hoehn-Saric et al., J. Clin. Psychiatry 49:8, Aug. 1988.
Shores et al., Comprehensive Psychiatry, vol. 33, No. 4, 237-244, 1992.
Rickels et al., JAMA, vol. 250, No. 6, Aug. 12, 1983.
Rickels et al., Arch. Gen. Psychiatry, vol. 45, May 1988.
Rickels et al., J. Clin. Psychopharmacology, vol. 10, No. 3, 1990.
Cecil Textbook of Medicine, 19th Ed., 2088-89, (1988).

Affiliated with

Also associated with

Rating

Treatments using venlafaxine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatments using venlafaxine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatments using venlafaxine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2994483